Stellaromics Revenue and Competitors
Employee Data
- Stellaromics has 37 Employees.
- Stellaromics grew their employee count by 147% last year.
Stellaromics's People
Name | Title | Email/Phone |
---|
Stellaromics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 11 | 10% | N/A | N/A |
#10 | $5.4M | 35 | 3% | N/A | N/A |
What Is Stellaromics?
Founded in 2022 and headquartered in Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations.\n\nStellaromics is currently in the advanced stages of developing its Pyxa™ suite of products, meticulously crafted to empower researchers and clinicians in the creation of intricate cellular maps, thereby amplifying our comprehension of various diseases.\n\nFor comprehensive details, we invite you to explore our website at stellaromics.com. Join us in shaping the future of biomedical research.\n\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show less
keywords:N/AN/A
Total Funding
37
Number of Employees
N/A
Revenue (est)
147%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.1M | 37 | 0% | $8.1M |
#2 | $6.1M | 37 | -23% | N/A |
#3 | $9.6M | 37 | 28% | N/A |
#4 | $6.2M | 37 | -7% | N/A |
#5 | $4.3M | 37 | N/A | N/A |